<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721979</url>
  </required_header>
  <id_info>
    <org_study_id>9582</org_study_id>
    <secondary_id>NCI-2016-00221</secondary_id>
    <secondary_id>9582</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02721979</nct_id>
  </id_info>
  <brief_title>Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance</brief_title>
  <official_title>A Phase 2 Study of Apalutamide in Active Surveillance Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well apalutamide works in treating patients with prostate
      cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer
      cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate
      cancer by blocking the use of testosterone by the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the negative repeat biopsy rate by site directed and systematic prostate biopsy
      after 90-days of apalutamide.

      SECONDARY OBJECTIVES:

      I. Determine the rate of exit at 2 years from active surveillance due to pathologic
      reclassification.

      II. Determine the overall rate of exit at 2 years from active surveillance.

      III. Determine the rate of local treatment (e.g. radical prostatectomy, radiation therapy,
      brachytherapy) at 2 years and the local treatment free survival.

      IV. Determine prostate-specific antigen (PSA) progression rates and PSA progression free
      survival (PFS), as defined by the Prostate Cancer Working Group 2 (PCWG2) criteria.

      V. Determine the rate of radiographic disappearance of magnetic resonance imaging (MRI)
      detectable prostate cancer following treatment (only in patients with a baseline nodule that
      is Prostate Imaging Reporting and Data System [PIRADS] 3 or more and &gt; 5mm).

      VI. Investigate the safety of apalutamide in men undergoing active surveillance; safety will
      be evaluated by the incidence, severity, duration, causality, seriousness, and type(s) of
      adverse events as assessed by the revised National Cancer Institute Common Toxicity Criteria
      (NCI CTC), version 4.03 published 14 June 2010.

      VII. Track quality of life utilizing the Functional Assessment of Cancer Therapy-Prostate
      (FACT-P) and Short Form (SF)36 surveys for each cohort.

      VIII. Exploratory biomarker assessment.

      OUTLINE:

      Patients receive apalutamide orally (PO) once daily (QD) for 90 days.

      After completion of the study treatment, patients are followed up at 180, 365, 545, and 730
      days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">November 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative (i.e. no residual carcinoma) site directed and systematic prostate biopsy rate</measure>
    <time_frame>At 90 days</time_frame>
    <description>Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100. A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above). The 95% confidence interval will be computed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in MYC/chromosome 8q24 via fluorescence in situ hybridization</measure>
    <time_frame>Baseline to up to 91 days</time_frame>
    <description>Fluorescence in situ hybridization will be conducted to assess for genomic alterations (loss or amplification) of the MYC gene, which is located on chromosome 8q24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed using the Functional Assessment of Cancer Therapy-Prostate surveys</measure>
    <time_frame>Baseline to up to 730 days</time_frame>
    <description>Functional Assessment of Cancer Therapy-Prostate is a validated quality of life survey specific for patients with prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed using the Short Form-36 survey</measure>
    <time_frame>Baseline to up to 730 days</time_frame>
    <description>Short Form-36 is a validated quality of life survey. This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in radiographic disappearance of magnetic resonance imaging detectable prostate cancer</measure>
    <time_frame>Baseline to up to 90 days</time_frame>
    <description>Only in patients with a baseline nodule that is Prostate Imaging Reporting and Data System 3 or more and &gt; 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>As assessed by National Cancer Institute Common Toxicity Criteria, version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local treatment free survival</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of men undergoing of local treatment</measure>
    <time_frame>At 2 years</time_frame>
    <description>Computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients exiting active surveillance due to pathologic reclassification</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients exiting active surveillance for any reason</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be computed along with its 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphatase and tensin homolog (PTEN) fluorescence in situ hybridization</measure>
    <time_frame>Baseline to up to 91 days</time_frame>
    <description>Fluorescence in situ hybridization will be conducted to assess for genomic loss of the PTEN gene.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen progression free survival as defined by the Prostate Cancer Working Group 2 criteria</measure>
    <time_frame>At 2 years</time_frame>
    <description>Prostate-specific antigen progression free survival will be estimated using Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen progression rate as defined by the Prostate Cancer Working Group 2 criteria (i.e. confirmed rising prostate-specific antigen &gt;= 2 ng/mL at least one week apart)</measure>
    <time_frame>At 2 years</time_frame>
    <description>Prostate-specific antigen progression rate will be computed along with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTEN immunohistochemistry</measure>
    <time_frame>Baseline to up to 91 days</time_frame>
    <description>Immunohistochemistry will be conducted to assess for loss of PTEN protein expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Up to 730 days</time_frame>
    <description>As assessed by National Cancer Institute Common Toxicity Criteria, version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor messenger ribonucleic acid expression profiling/risk classification (e.g. Decipher or ribonucleic acid-seq)</measure>
    <time_frame>Baseline to up to 91 days</time_frame>
    <description>Messenger ribonucleic acid expression profiling will be conducted using the Decipher assay and/or ribonucleic acid-seq.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Stage II Prostate Adenocarcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive apalutamide PO QD for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (apalutamide)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed an informed consent document

          -  Be willing/able to adhere to the prohibitions and restrictions specified in this
             protocol

          -  Written authorization for use and release of health and research study information has
             been obtained

          -  Life expectancy &gt;= 10 years (as determined by the treating physician)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1

          -  Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12
             core prostate biopsy completed within 1-year of enrollment (note: most recent prostate
             biopsy must have demonstrated prostatic adenocarcinoma)

          -  Favorable risk prostate cancer as defined by:

               -  Very low-risk:

                    -  Clinical stage T1c disease

                    -  PSA density (PSAD) &lt; 0.15 ng/mL

                    -  Gleason score 6

                    -  =&lt; 2 core biopsies with =&lt; 50% involvement of any biopsy core with cancer,
                       or unilateral disease =&lt; 2 core biopsies with any percentage involvement OR

               -  Low risk:

                    -  Clinical stage =&lt; T2a

                    -  PSA &lt; 10 ng/mL

                    -  Gleason score 6 OR

               -  Low-intermediate risk:

                    -  Clinical stage T1c

                    -  PSA &lt; 10 ng/ml

                    -  Gleason 3+4 present in =&lt; 50% of one core/site as detected by systematic
                       biopsy or MRI/transrectal ultrasound (TRUS) fusion guided biopsy

                    -  Gleason 6 disease in all other cores (maximum of 2 cores with =&lt; 50%
                       involvement of any core, or if unilateral disease, any percentage
                       involvement)

          -  Willing and qualified for active surveillance at Johns Hopkins or the University of
             Washington

          -  Serum testosterone &gt;= 150 ng/dL

          -  Able to swallow the study drugs whole as a tablet

          -  Hemoglobin &gt;= 9.0 g/dL, independent of transfusion and/or growth factors within 3
             months prior to randomization

          -  Platelet count &gt;= 100,000 x 10^9/uL independent of transfusion and/or growth factors
             within 3 months prior to randomization

          -  Serum albumin &gt;= 3.0 g/dL

          -  Glomerular filtration rate (GFR) &gt;= 45 mL/min

          -  Serum potassium &gt;= 3.5 mmol/L

          -  Serum total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (note: in subjects with
             Gilbert's syndrome, if total bilirubin is &gt; 1.5 x ULN, measure direct and indirect
             bilirubin and if direct bilirubin is =&lt; 1.5 x ULN, subject may be eligible)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5 Ã— ULN

          -  Medications known to lower the seizure threshold must be discontinued or substituted
             at least 4 weeks prior to study entry

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

        Exclusion Criteria:

          -  Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation
             therapy, brachytherapy)

          -  Prior use of ARN-509 (apalutamide)

          -  Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its
             excipients

          -  Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (e.g. leuprolide, goserelin, triptorelin)

               -  Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)

               -  Antiandrogens (e.g. bicalutamide, nilutamide)

               -  Second generation antiandrogens (e.g. enzalutamide)

               -  Immunotherapy (e.g. sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g. docetaxel, cabazitaxel)

          -  Have any condition that, in the opinion of the investigator, would compromise the
             well-being of the subject or the study or prevent the subject from meeting or
             performing study requirements

          -  History of any of the following:

               -  Seizure or known condition that may pre-dispose to seizure (including but not
                  limited to prior stroke, transient ischemic attack, loss of consciousness within
                  1 year prior to randomization, brain arteriovenous malformation; or intracranial
                  masses such as schwannomas and meningiomas that are causing edema or mass effect)

               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
                  failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,
                  cerebrovascular accident including transient ischemic attacks), or clinically
                  significant ventricular arrhythmias within 6 months prior to randomization

               -  Any condition that in the opinion of the investigator, would preclude
                  participation in this study

          -  Current evidence of any of the following:

               -  Uncontrolled hypertension

               -  Gastrointestinal disorder affecting absorption

               -  Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis) or
                  other medical condition that would make prednisone/prednisolone (corticosteroid)
                  use contraindicated

               -  Any condition that in the opinion of the investigator, would preclude
                  participation in this study

          -  The use of drugs known to lower the seizure threshold, including: atypical
             antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion,
             lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine,
             mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline,
             desipramine, doxepin, imipramine, maprotiline, mirtazapine)

          -  The use of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
             inhibitors, including: itraconazole, clarithromycin, erythromycin, diltiazem,
             verapamil, delavirdine, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,
             saquinavir, telithromycin, voriconazole, grapefruit juice (or grapefruits)

               -  Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for
                  enrollment if they can safely stop said medication; a two week or 5 half-lives,
                  whichever is longer, washout will be required prior to enrolling on study;
                  subject may not resume medication while receiving apalutamide

          -  Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin,
             rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort

          -  Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for
             enrollment if they can safely stop said medication; a two week or 5 half-lives,
             whichever is longer, washout will be required prior to enrolling on study; subject may
             not resume medication while receiving apalutamide

          -  Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schweizer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth J. Pienta</last_name>
      <email>kpienta1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth J. Pienta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schweizer</last_name>
      <phone>206-288-6252</phone>
      <email>schweize@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schweizer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

